Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.

Dipeptidyl peptidase-4 inhibitors up risk of bullous pemphigoid

28 May 2018

Use of dipeptidyl peptidase-4 inhibitors (DPP4is), particularly vildagliptin, appears to increase the risk for developing bullous pemphigoid (BP), according to a recent study.

“Their use needs to be carefully evaluated, particularly in high-risk patients, such as males and those aged 80 years or older,” the authors said.

A total of 61 patients with diabetes and BP and 122 controls were included in the study. There was an association between DPP4is and an increased risk for BP development (adjusted odds ratio [AOR], 2.64; 95 percent CI, 1.19–5.85; p=0.02), with vildagliptin showing the highest AOR (3.57; 1.07–11.84; p=0.04).

In stratified analysis, a stronger association was seen in males and patients aged 80 years. In addition, DPP4i withdrawal and the initiation of first-line treatments resulted in clinical remission in 95 percent of patients.

These findings support those of a recent case report and literature review, which found that DPP4is may trigger the onset of BP similarly to a thermal burn. Additionally, researchers suggested that the clinical and histopathological features of DPP4i-induced BP may be distinct from other types of BP. [Front Immunol 2018;9:542]

To assess the link between DPP4i treatment and BP development, the authors conducted a retrospective 1:2 case-control study, comparing case patients with diabetes and BP with age- and sex-matched controls with diabetes issued from Swiss and French dermatologic departments from 1 January 2014 and 31 July 2016.

The study was limited by its design and focus on DPP4i intake without analysing the potential isolated effect of metformin, according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.